Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology

Journal of Psychopharmacology

Volumn 19, Issue 6, 2005, Pages 567-596

  Baldwin, David S ^a   Anderson, Ian M ^b   Nutt, David J ^c   Bandelow, Borwin ^d   Bond, A ^e   Davidson, Jonathan R T ^f   Den Boer, J A ^g   Fineberg, Naomi A ^h   Knapp, Martin ^e   Scott, J ^e   Wittchen, H U ⁱ  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

ⁱ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Anticonvulsants; Antidepressants; Antipsychotics; Anxiety disorders; Anxiolytics; Benzodiazepines; Cognitive behaviour therapy; Evidence based guidelines; Generalized anxiety disorder; Obsessive compulsive disorder; Panic disorder

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHENELZINE; REBOXETINE; RECEPTOR BLOCKING AGENT; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BLOOD DYSCRASIA; BREAST FEEDING; COGNITION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EVIDENCE BASED MEDICINE; FEEDBACK SYSTEM; FLU LIKE SYNDROME; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSOMNIA; INTERNATIONAL CLASSIFICATION OF DISEASES; LONG TERM CARE; MEDICAL CARE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MEMORY DISORDER; MENTAL HEALTH SERVICE; MOTOR DYSFUNCTION; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BEHAVIOR THERAPY; BREAST FEEDING; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 27644534854     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105059253     Document Type: Review

References (265)

1. Ackerman D L, Greenland S (2002) Multivariate meta-analysis of controlled drugs studies for obsessive compulsive disorder. J Clin Psychopharmacol 22: 309-317
2. Albus M, Scheibe G (1993) Outcome of panic disorder with or without concomitant depression: A 2-year prospective follow-up study. Am J Psychiatry 150: 1878-1880
3. Allgulander C, Hackett D, Salinas E (2001) Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder: twenty-four week placebo-controlled dose-ranging study. Br J Psychiatry 179: 15-22
4. Allgulander C, Huusom AKT, Florea I (2005) Escitalopram for relapse prevention in generalized anxiety disorder (GAD). Poster presentation, ADAA meeting, March
5. Allgulander C, Mangano R, Zhang J, Dahl A A, Lepola U, Sjodin I, Emilien G. (2004) Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Human Psychopharmacology 19: 387-396
6. Allgulander C, Bandelow B, Hollander E, Montgomery S A, Nutt D J, Okasha A, Pollack M H, Stein D J, Swinson R P: World Council of Anxiety (2003) WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectrums 8 (Suppl. 1): 53-61
7. Allgulander C, Dahl A A, Austin C (2004) Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161: 1642-1649
8. Altamura A C, Pioli R, Vitto M, Mannu P (1999) Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor nonresponders. Int Clin Psychopharmacol 14: 239-245
9. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, 1994. Washington, DC
10. Amering M, Katschnig H, Berger P, Windhaber J, Baischer W, Dantendorfer K (1997) Embarrassment about the first panic attack predicts agoraphobia in panic disorder patients. Behav Res Ther 35: 517-521
11. Anderson I M, Nutt D J, Deakin J F (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 14: 3-20
12. Andlin-Sobocki P, Wittchen H U (2005) Cost of anxiety disorders in Europe. Eur J Neurol 12 (Suppl. 1): 39-44
13. Angst J, Gamma A, Endrass J, Hantouche E, Goodwin R, Ajdacic V, Eich D, Rossler W (2005) Obsessive-compulsive syndromes and disorders: Significance of comorbidity with bipolar and anxiety syndromes. Eur Arch Psychiatry Clin Neurosci 255: 65-71
14. Ashton H, Young A H (2003) GABA-ergic drugs: exit stage left, enter stage right. J Psychopharmacol 17: 174-178
15. Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002) Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17: 115-119
16. Bakker A, van Balkom A J, Spinhoven P, Blaauw B M, van Dyck R (1998) Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. J Nerv Ment Dis 186: 414-419
17. Baldwin D S (2004) Sexual dysfunction associated with antidepressant drugs. Expert Opinion on Drug Safety 3: 457-470
18. Baldwin D S, Birtwistle J (1998) The side effect burden associated with drug treatment of panic disorder. J Clin Psychiatry 59 (Suppl. 8): S39-S44
19. Baldwin D S, Polkinghorn C (2005) Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 8: 293-302
20. Baldwin D S, Huusom A K T, Maehlum E (2004) Escitalopram and paroxetine compared to placebo in generalised anxiety disorder. Eur Neuropsychopharmacol 14: (Suppl. 3): S311-S312
21. Ballenger J C, Wheadon D E, Steiner M, Bushnell W, Gergel I P (1998) Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 755: 36-42
22. Ballenger J C, Davidson J R, Lecrubier Y, Nutt D J, Baldwin D S, den Boer J A, Kasper S, Shear M K (1998) Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59 (Suppl. 8): 47-54
23. Ballenger J C, Davidson J R, Lecrubier Y, Nutt D J, Bobes J, Beidel D C, Ono Y, Westenberg H G (1998) Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59 (Suppl. 17): 54-60
24. Ballenger J C, Davidson J R, Lecrubier Y, Nutt D J, Borkovec T D, Rickels K, Stein D J, Wittchen H U (2001) Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 62 (Suppl. 11): 53-58
25. Ballenger J C, Davidson J R, Lecrubier Y, Nutt D J, Marshall R D, Nemeroff C B, Shalev A Y, Yehuda R (2004) Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 65 (Suppl. 1): 55-62
26. Bandelow B, Zohar J, Hollander E, Kasper S, Möller H J, World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (2002.) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3: 171-199
27. Barlow D H, Gorman J M, Shear M K, Woods S W (2000). Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 283: 2529-2536
28. Barr L C, Goodman W K, Anand A, McDougle C J, Price L H (1997). Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 154: 1293-1295
29. Benjamin J, Ben-Zion I Z, Karbofsky E, Dannon P (2000) Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl.) 149: 194-196
30. Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L (2004) Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37: 206-210
31. Bielski R J, Bose A, Chang C-C (2004) A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Presented at the 42nd Annual Meeting of the American College of Neuropsychopharmacology, December 7-11, San Juan, Puerto Rico
32. Bjelland I, Dahl A A, Haug T T, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52: 69-77
33. Blanco C, Raza M S, Schneier F, Liebowitz M R (2003) The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol 6: 427-442
34. Blier P, Bergeron R (1996) Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 11: 37-44
35. Blomhoff S, Haug T T, Hellstrom K, Holme I, Humble M, Madsbu H P, Wold J E (2001) Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179: 23-30
36. Bower P, Richards D, Lovell K (2001) The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: a systematic review. Br J Gen Pract 51: 838-845
37. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E (1998) Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 155: 603-609
38. Brown T A, Antony M M, Barlow D H (1995) Diagnostic comorbidity in panic disorder: effect on treatment outcome and course of comorbid diagnoses following treatment. J Consult Clin Psychol 63: 408-418
39. Carlbring P, Ekselius L, Andersson G (2003) Treatment of panic disorder via the Internet: a randomized trial of CBT vs. applied relaxation. J Behav Ther Exp Psychiatry 34: 129-140
40. Clark D M, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T (2003) Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. Journal of Consulting and Clinical Psychology 71: 1058-1067
41. Committee on Safety of Medicines (2004). Safety of selective serotonin reuptake inhibitor antidepressants. 6 December
42. Costello E J, Mustillo S, Erkanli A, Keeler G, Angold A (2003) Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 60: 837-844
43. Cottraux J, Mollard E, Bouvard M, Marks I (1993) Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Res 49: 63-75
44. Cottraux J, Note I D, Cungi C, Legeron P, Heim F, Chneiweiss L, Bernard G, Bouvard M (1995) A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 167: 635-641
45. Cowley D S, Flick S N, Roy-Byrne P P (1996) Long-term course and outcome in panic disorder: a naturalistic follow-up study. Anxiety 2: 13-21
46. Dannon P N, Iancu I, Grunhaus L (2002) Psychoeducation in panic disorder patients: effect of a self-information booklet in a randomized, masked-rater study. Depress Anxiety 16: 71-76
47. Dannon P N, Sasson Y, Hirschmann S, Iancu I, Grunhaus L J, Zohar J (2000) Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 10: 165-169
48. Dannon P N, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M (2004) Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry 4: 16
49. Davidson J, Pearlstein T, Londborg P, Brady K T, Rothbaum B, Bell J, Maddock R, Hegel M T, Farfel G (2001) Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 158: 1974-1981
50. Davidson J R, Baldwin D S, Stein D J (2004) Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release: A 6-Month Randomized, Controlled Trial. Presented at American College of Neuropsychopharmacology, Puerto Rico, December
51. Davidson J R (2005) Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacology 25: 166-169
52. Davidson JRT, Foa E B, Huppert J, Keefe F J, Franklin M E, Compton J S, Zhao N (2004) Fluoxetine, comprehensive cognitive behavioral therapy (CCBT) and placebo in generalized social anxiety disorder. Arch Gen Psychiatry 61: 1005-1013
53. Davies SJC, Jackson R P, Potokar J, Nutt D J (2004) Treatment of anxiety and depressive disorders in patients with cardiovascular disease. BMJ 328: 939-943
54. Davis L L, Jewell M E, Ambrose S, Farley J, English B, Bartolucci A, Petty F (2004) A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. J Clin Psychopharmacol 24: 291-297
55. Den Boer J A, Westenberg H G (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3: 59-74
56. Den Boer J A (1998) Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry 59 (Suppl. 8): 30-36
57. Den Boer P C, Wiersma D, Van den Bosch R J (2004) Why is self-help neglected in the treatment of emotional disorders? A meta-analysis. Psychol Med 34:959-971
58. Denys D, de Geus F, van Megen H J, Westenberg H G (2004) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65: 1040-1048
59. Dowell A C, Biran L A (1990) Problems in using the hospital anxiety and depression scale for screening patients in general practice. Br J Gen Pract 40: 27-28
60. Durham R C, Turvey A A (1987). Cognitive therapy versus behaviour therapy in the treatment of chronic generalised anxiety. Behav Res Ther 25: 229-234
61. Durham R C, Chambers J A, MacDonald R R, Power K G, Major K (2003) Does cognitive-behavioural therapy influence the long-term outcome of generalized anxiety disorder? An 8-14 year follow-up of two clinical trials. Psychol Med 33: 499-509
62. Durham R C, Chambers J A, Power K G, Sharp D M, Macdonald R, Makor K A, Dow MGT, Gumpley A I (in press) Long-term outcome of cognitive behavior therapy clinical trials in central Scotland. Health Technology Assessment
63. Ehlers A, Clark D M, Hackmann A, McManus F, Fennell M, Herbert C, Mayou R (2003) A randomized controlled trial of cognitive therapy, a self-help booklet, and repeated assessments as early interventions for posttraumatic stress disorder. Arch Gen Psychiatry. 60: 1024-1032
64. El-Khayat R, Baldwin D S (1998) Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. J Psychopharmacol 12: 323-329
65. Eng W, Heimberg R G, Coles M E, Schneier F R, Liebowitz M R (2000) An empirical approach to subtype identification in individuals with social phobia. Psychol Med 30: 1345-1357
66. Erwin B A, Heimberg R G, Juster H, Mindlin M (2002) Comorbid anxiety and mood disorders among persons with social anxiety disorder. Behav Res Ther 40: 19-35
67. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L (2005) Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 75: 69-74
68. Fallon B A, Liebowitz M R, Campeas R, Schneier F R, Marshall R, Davies S, Goetz D, Klein D F (1998) Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 55: 918-924
69. Faravelli C, Zucchi T, Viviani B, Salmoria R, Perone A, Paionni A, Scarpato A, Vigliaturo D, Rosi S, D'adamo D, Bartolozzi D, Cecchi C, Abrardi L (2000) Epidemiology of social phobia: a clinical approach. Eur Psychiatry 15: 17-24
70. Fehm L, Pelissolo A, Furmark T, Wittchen H U (2005) Size and burden of social phobia in Europe. Eur Neuropsychopharmacol 75: 453-462
71. Feltner D E, Crockatt J G, Dubovsky S J (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23: 240-249
72. Fineberg N A, Gale T M (2005) Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8: 107-129
73. Fineberg N A, Heyman I, Jenkins R, Premkumar P, Veale D, Kendall T, Freeston M (2004) Does childhood and adult obsessive compulsive disorder (OCD) respond the same way to treatment with serotonin reuptake inhibitors? Eur Neuropsychopharmacol 14 (Suppl. 3): 191-192
74. Fisher P L, Durham R C (1999) Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med 29: 1425-1434
75. Flint AJ (1994) Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 151: 640-649
76. Foa E B, Liebowitz M R, Kozak M J, Davies S, Campeas R, Franklin M E, Huppert J D, Kjernisted K, Rowan V, Schmidt A B, Simpson H B, Tu X (2005) Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162: 151-61
77. Fontana A, Rosenheck R (1997) Effectiveness and cost of the inpatient treatment of posttraumatic stress disorder: comparison of three models of treatment. Am J Psychiatry 154: 758-765
78. Friedman M J, Davidson JRT, Mellman T A (2000) Pharmacotherapy. In Foa E B, Keane T M, Friedman M J (eds) Effective Treatments for PTSD: Practice Guidelines from the International Society for Stress Studies. Guilford Press, New York, pp. 84-105
79. Frommberger LJ, Stieglitz R D, Nyberg E (2004) Comparison between paroxetine and behaviour therapy in patients with posttraumatic stress disorder (PTSD): a pilot study. Int J Psychiatry Clin Pract 8: 19-23
80. Fux M, Benjamin J, Belmaker R H (1999) Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol 2: 193-195
81. Geller D A, Biederman J, Stewart S E, Mullin A, Spencer T, Faraone S V (2003) Which SSRI? A meta-analysis of pharmacotherapy trials in paediatric obsessive-compulsive disorder. Am J Psychiatry 160: 1919-1928
82. Gelpin E, Bonne O, Peri T, Brandes D, Shalev A Y (1996) Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 57: 390-394
83. Goisman R M, Warshaw M G, Steketee G S, Fierman E J, Rogers M P, Goldenberg I, Weinshenker N J, Vasile R G, Keller M B (1995) DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. Am J Psychiatry 152: 1438-1443
84. Goldberg D, Bridges K (1987) Screening for psychiatric illness in general practice: the general practitioner versus the screening questionnaire. J R Coll Gen Pract 37: 15-18
85. Goodwin G M: Consensus Group of the British Association for Psychopharmacology (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17: 149-173
86. Goodwin R D, Faravelli C, Rosi S, Cosci F, Truglia E, de Graaf R, Wittchen H U (2005) Size and burden of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol 15: 435-443
87. Gould R A, Otto M W, Pollack M H (1997) Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behav Ther 28: 285-305
88. Grady T A, Pigott T A, L'Heureux F, Hill J L, Bernstein S E, Murphy D L (1993) Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 150: 819-821
89. Greenberg P E, Sisitsky T, Kessler R C, Finkelstein S N, Berndt E R, Davidson J R, Ballenger J C, Fyer A J (1999) The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 60: 427-435
90. Greist J H, Marks I M, Baer L, Kobak K A, Wenzel K W, Hirsch M J, Mantle J M, Clary C M (2002) Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry 63: 138-145
91. Greist J H, Bandelow B, Hollander E, Marazziti D, Montgomery S A, Nutt D J, Okasha A, Swinson R P, Zohar J, World Council of Anxiety (2003) WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectrums 8 (Suppl. 1): 7-16
92. Greist J H, Jefferson J W, Kobak K A, Chouinard G, DuBoff E, Halaris A, Kim S W, Koran L, Liebowtiz M R, Lydiard B (1995) A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 10: 57-65
93. Guest J, Russ J, Lenox-Smith A (2005) Cost effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom. Eur J Health Econom 6: 136-145
94. Hamner M B, Faldowski R A, Ulmer H G, Frueh B C, Huber M G, Arana G W (2003) Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 18: 1-8
95. Haug T T, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu H P, Wold J E (2003) Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry 182: 312-318
96. Haynes R B, Devereaux P J, Guyatt G H (2002) Physicians' and patients' choices in evidence based practice. BMJ 324: 1350
97. Heimberg R G (2002) Cognitive-behavioral therapy for social anxiety disorder: current status and future directions. Biol Psychiatry 57: 101-108
98. Heimberg R G, Liebowitz M R, Hope D A, Schneier F R, Holt C S, Welkowitz L A, Juster H R, Campeas R, Bruch M A, Cloitre M, Fallon B, Klein D F (1998) Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 55: 1133-1141
99. Heldt E, Manfro G G, Kipper L, Blaya C, Maltz S, Isolan L, Hirakata V N, Otto M W (2003) Treating medication-resistant panic disorder: predictors and outcome of cognitive-behavior therapy in a Brazilian public hospital. Psychother Psychosom 72: 43-48
100. Hertzberg M A, Butterfield M I, Feldman M E, Beckham J C, Sutherland S M, Connor K M, Davidson JR (1999) A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 45: 1226-1229
101. Hirschmann S, Dannon P N, Iancu I, Dolberg O T, Zohar J, Grunhaus L (2000) Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 20: 556-559
102. Hoehn-Saric R, Ninan P, Black D W, Stahl S, Greist J H, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W (2000) Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 57: 76-82
103. Hohagen F, Winkelmann G, Rasche-Ruchle H, Hand I, Konig A, Munchau N, Hiss H, Geiger-Kabisch C, Kappler C, Schramm P, Rey E, Aldenhoff J, Berger M (1998) Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry 35 (Suppl.): 71-78
104. Hollander E, Baldini Rossi N, Sood E, Pallanti S (2003) Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 6: 397-401
105. Hollander E, Allen A, Steiner M, Wheadon D E, Oakes R, Burnham D B, Paroxetine OCD Study Group (2003) Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64: 1113-1121
106. Hoyer J, Wittchen H U (2003) Generalized anxiety disorders in primary medical care. Versicherungsmedizin 55: 127-135
107. Huppert J D, Schultz L T, Foa E B, Barlow D H, Davidson J R, Gorman J M, Shear M K, Simpson H B, Woods S W (2004) Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry 161: 1485-1487
108. Husted D S, Shapira N A (2004) A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation. CNS Spectr 9: 833-847
109. Issakidis C, Sanderson K, Corry J, Andrews G, Lapsley H (2004) Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol Med 34: 19-35
110. Jorm A F, Christensen H, Griffiths K M, Parslow R A, Rodgers B, Blewitt K A (2004) Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Aust 181 (Suppl.): S29-S46
111. Kampman M, Keijsers G P, Hoogduin C A, Hendriks G J (2002) A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry 63: 772-777
112. Kapczinski F, Schmitt R, Lima M S (2003) The use of antidepressants for generalized anxiety disorder. Cochrane Database of Systematic Reviews
113. Katon W J, Roy-Byrne P, Russo J, Cowley D (2002) Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psychiatr 95: 1098-1104
114. Katz R J, DeVeaugh-Geiss J, Landau P (1990) Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 28: 401-414
115. Katz I R, Reynolds C F 3rd, Alexopoulos G S, Hackett D (2002) Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 50: 18-25
116. Kessler R C, Stein M B, Berglund P (1998) Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 155: 613-619
117. Kessler R C, Sonnega A, Bromet E, Hughes M, Nelson C B (1995) Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 52: 1048-1060
118. Kessler R C, McGonagle K A, Zhao S, Nelson C B, Hughes M, Eshleman S, Wittchen H U, Kendler K S (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19
119. Kessler R C, DuPont R L, Berglund (1999) Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 756: 1915-1923
120. Khan A, Brodhead A E, Kolts R L, Brown W A (2005) Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 39: 145-150
121. Kobak K A, Greist J H, Jefferson J W, Katzelnick D J, Henk H J (1998) Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl) 136: 205-216
122. Lader M H, Bond A J (1998) Interaction of pharmacological and psychological treatments of anxiety. Br J Psychiatry 173 (Suppl. 34): 42-48
123. Lader M, Scotto J C (1998) A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacol 139: 402-406
124. Lader M, Slender K, Burger V, Nil R (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety 19: 241-248
125. Langs G, Quehenberger F, Fabisch K, Klug G, Fabisch H, Zapotoczky H G (2000) The development of agoraphobia in panic disorder: a predictable process? J Affect Disord 58: 43-50
126. Lecrubier Y, Judge R (1997) Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95: 153-160
127. Lecrubier Y, Wittchen H U, Faravelli C, Bobes J, Patel A, Knapp M (2000) A European perspective on social anxiety disorder. Eur Psychiatry 15: 5-16
128. Lelliott P, Marks I, McNamee G, Tobena A (1989) Onset of panic disorder with agoraphobia. Toward an integrated model. Arch Gen Psychiatry 46: 1000-1004
129. Lenze E J, Mulsant B H, Shear M K, Dew M A, Miller M D, Pollock B G, Houck P, Tracey B, Reynolds C F 3rd (2005) Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry 162: 146-150
130. Lepola U M, Wade A G, Leinonen E V, Koponen H J, Frazer J, Sjodin I, Penttinen J T, Pedersen T, Lehto H J (1998). A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59: 528-534
131. Lewis G, Wessely S (1990) Comparison of the General Health Questionnaire and the Hospital Anxiety and Depression Scale. Br J Psychiatry 157: 860-864
132. Lidren D M, Watkins P L, Gould R A, Clum G A, Asterino M, Tulloch H L (1994) A comparison of bibliotherapy and group therapy in the treatment of panic disorder. Consult Clin Psychol 62: 865-869
133. Lieb R, Becker E, Altamura C (2005) The epidemiology of generalized anxiety disorder in Europe. Eur J Neuropsychopharmacol 75: 445-452
134. Liebowitz M R, Gelenberg A J, Munjack D (2005) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62: 190-198
135. Liebowitz M R, Stein M B, Tancer M, Carpenter D, Oakes R, Pitts C D (2002) A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63: 66-74
136. Liebowitz M R, Heimberg R G, Schneier F R, Hope D A, Davies S, Holt C S, Goetz D, Juster H R, Lin S H, Bruch M A, Marshall R D, Klein D F (1999) Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 10: 89-98
137. Lingford-Hughes A R, Welch S, Nutt D J: British Association for Psychopharmacology (2004) Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 18: 293-335
138. Llorca P M, Sapdone C, Sol O (2002) Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a three-month double-blind study. J Clin Psychiatry 63, 1020-1027
139. Londborg P D, Hegel M T, Goldstein S, Goldstein D, Himmelhoch J M, Maddock R, Patterson W M, Rausch J, Farfel G M (2001) Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 62: 325-331
140. McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro D A, Ilson S, Gray J A, Goldberg D, Mann A, Marks I, Everitt B, Tylee A (2004) Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 185: 55-62
141. McDougle C J, Price L H, Goodman W K, Charney D S, Heninger G R (1991) A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 77: 175-184
142. McDougle C J, Goodman W K, Leckman J F, Lee N C, Heninger G R, Price L H (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 57: 302-308
143. McDougle C J, Epperson C N, Pelton G H, Wasylink S, Price L H (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57: 794-801
144. McGlashan T H, Grilo C M, Skodol A E, Gunderson J G, Shea M T, Morey L C, Zanarini M C, Stout R L (2000) The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand 102: 256-264
145. Mann A H, Jenkins R, Belsey E (1981) The twelve-month outcome of patients with neurotic illness in general practice. Psychol Med 11: 535-550
146. Marks I M, Lelliott P, Basoglu M, Noshirvani H, Monteiro W, Cohen D, Kasvikis Y (1988) Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 152: 522-534
147. Martenyi F, Brown E B, Zhang H, Koke S C, Prakash A (2002) Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 181: 315-320
148. Martinsen E W, Olsen T, Tonset E, Nyland K E, Aarre T F (1998) Cognitive-behavioral group therapy for panic disorder in the general clinical setting: a naturalistic study with 1-year follow-up. J Clin Psychiatry 59: 437-442
149. Mavissakalian M, Michelson L, Dealy R S (1983) Pharmacological treatment of agoraphobia: Imipramine versus imipramine with programmed practice. Br J Psychiatry 143: 348-355
150. Mavissakalian M R, Perel J M (1999) Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 56: 821-827
151. Meibach R C, Dunner D, Wilson L G (1987) Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiatry 84: 355-358
152. Mendels J, Krajewski T F, Huffer V (1986) Effective short-term treatment of anxiety: a double-blind trial. J Clin Psychiatry 47: 170-174
153. Meoni P, Hackett D, Lader M (2004) Pooled analysis of venlafaxine WXR efficacy on somatic and psychic symptoms of anxiety in generalized anxiety disorder. Depress Anx 19: 127-132
154. Michelson D, Pollack M, Lydiard R B, Tamura R, Tepner R, Tollefson G
155. Michelson D, Lydiard R B, Pollack M H, Tamura R N, Hoog S L, Tepner R, Demitrack M A, Tollefson G D (1998) Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 155: 1570-1577
156. Mitte K, Noack P, Steil R, Hautzinger M (2005) A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25: 141-150
157. Möller H-J, Volz V P, Reimann I W (2001) Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 27: 59-65
158. Monnelly E P, Ciraulo D A, Knapp C, Keane T (2003) Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 23: 193-196
159. Montgomery S A, Kasper S, Stein D J, Bang Hedegaard K, Lemming O M (2001) Citalopram 20mg, 40mg and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 16: 75-86
160. Montgomery S A, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood A J (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 3: 143-152
161. Montgomery S A, Sheehan D V, Meoni P (2002) Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatric Res 36: 209-217
162. Mundo E, Guglielmo E, Bellodi L (1998) Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 13: 219-224
163. Munjack D J, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, McManus M, McDowell D, Palmer R, Leonard M (1989) Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 9: 22-27
164. National Institute for Clinical Excellence (2002) Guidance on the use of computerised cognitive behavioural therapy for anxiety and depression. Health Technology Appraisal Guidance 51. London
165. National Institute for Clinical Excellence (2004) Depression. Management of depression in primary and secondary care. Clinical Guideline 23. National Collaborating Centre for Mental Health, London. December
166. National Institute for Clinical Excellence (2004) The management of panic disorder and generalised anxiety disorder in primary and secondary care. National Collaborating Centre for Mental Health, London. December
167. National Institute for Clinical Excellence (2004) Obsessive compulsive disorder: core interventions in the treatment of obsessive compulsive disorder and body dysmorphophobic disorder. Draft for consultation, February
168. National Institute for Clinical Excellence (2005) Post-traumatic stress disorder. The management of PTSD in adults and children in primary and secondary care. National Clinical Practice Guideline number 26. The Royal College of Psychiatrists and the British Psychological Society, London
169. Nease D E Jr, Aikens J E (2003) DSM depression and anxiety criteria and severity of symptoms in primary care: cross sectional study. BMJ 327: 1030-1031
170. Nulman I, Rovet J, Stewart D E (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159: 1889-1895
171. Nutt D J (2003) Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 17: 355-364
172. Nutt D J (2005a) Death by tricyclic: the real antidepressant scandal? J Psychopharmacol 19: 123-124
173. Nutt D J (2005b) Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums 10: 49-56
174. Nuttin B J, Gabriels L A, Cosyns P R, Meyerson B A, Andreewitch S, Sunaert S G, Maes A F, Dupont P J, Gybels J M, Gielen F, Demeulemeester H G (2003) Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery 52: 1263-1274
175. Oehrberg S, Christiansen P E, Behnke K, Borup A L, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom J K, Manniche P M (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167: 374-379
176. Oosterbaan D B, van Balkom A J, Spinhoven P, van Dyck R (2001) The placebo response in social phobia. J Psychopharmacol 75: 199-203
177. Ormel J, Koeter M W, van den Brink W, van de Willige G (1991) Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 48: 700-706
178. Ormel J, Oldehinkel T, Brilman E, van den Brink W (1993) Outcome of depression and anxiety in primary care. A three-wave 3 1/2-year study of psychopathology and disability. Arch Gen Psychiatry 50: 759-766
179. Ormel J, Van Den Brink W, Koeter M W, Giel R, Van Der Meer K, Van De Willige G, Wilmink F W (1990) Recognition, management and outcome of psychological disorders in primary care: a naturalistic follow-up study. Psychol Med 20: 909-923
180. Ost L G, Ferebee I, Furmark T (1997) One-session group therapy of spider phobia: direct versus indirect treatments. Behav Res Ther 35: 721-732
181. Otto M W, Pollack M H, Penava S J, Zucker B G (1999) Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav Res Ther 37: 763-770
182. Otto M W, Tuby K S, Gould R A, McLean R Y, Pollack M H (2001) An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 158: 1989-1992
183. Otto M W, Pollack M H, Gould R A, Worthington J J 3rd, McArdle E T, Rosenbaum J F (2000) A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord 14: 345-358
184. Pande A C, Feltner D E, Jefferson J W, Davidson J R, Pollack M, Stein M B, Lydiard R B, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney C A, Werth J L (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24: 141-149
185. Parkerson G R Jr, Broadhead W E (1997) Screening for anxiety and depression in primary care with the Duke Anxiety-Depression Scale. Fam Med 29: 177-181
186. Patel A, Knapp M, Henderson J, Baldwin D S (2002) The economic consequences of social phobia. J Affect Disord 68: 221-233
187. Pigott T A, L'Heureux F, Hill J L, Bihari K, Bernstein S E, Murphy D L (1992) A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12: 11-18
188. Pigott T A, Pato M T, L'Heureux F, Hill J L, Grover G N, Bernstein S E, Murphy D L (1991) A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 11: 242-248
189. Pitman R K, Sanders K M, Zusman R M, Healy A R, Cheema F, Lasko N B, Cahill L, Orr S P, Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 57: 189-192
190. Pollack M H, Whitaker T, Mangano R, Tzanis E (2004) A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder. Presented at American College of Neuropsychopharmacology, December
191. Pollack M H, Otto M W, Kaspi S P, Hammerness P G, Rosenbaum J F (1994) Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry 55: 200-205
192. Pollack M H, Allgulander C, Bandelow B, Cassano G B, Greist J H, Hollander E, Nutt D J, Okasha A, Swinson R P, World Council of Anxiety (2003) WCA recommendations for the long-term treatment of panic disorder. CNS Spectrums 8 (Suppl. 1): 17-30
193. Power K G, Simpson R J, Swanson V (1990) Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br J Gen Pract 40: 289-294
194. Proudfoot J, Ryden C, Everitt B, Shapiro D A, Goldberg D, Mann A, Tylee A, Marks I, Gray J A (2004) Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 185: 46-54
195. Rapaport M H, Wolkow R, Rubin A, Hackett E, Pollack M, Ota K Y (2001) Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104: 289-298
196. Rasmussen S A, Eisen J L (1990) Epidemiology of obsessive compulsive disorder. J Clin Psychiatry 51 (Suppl.): 10-14
197. Ribeiro L, Busnello J V, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello E A, Kapczinski F (2001) Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34: 1303-1307
198. Rice D P, Miller L S (1998) Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 34 (Suppl.): 4-9
199. Rickels K, Schweizer E, Case W G, Greenblatt D J (1990) Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 47: 899-907
200. Rickels K, London J, Fox I, Hassman H, Csanalosi I, Weise C (1991) Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: a controlled study. Pharmacopsychiatry 24: 127-131
201. Rickels K, Pollack M H, Sheehan D V (2000) Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am J Psychiatry 157: 968-974
202. Rickels K, Zaninelli R, McCafferty J P (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160: 749-756
203. Rief W, Trenkamp S, Auer C, Fichter M M (2000) Cognitive behavior therapy in panic disorder and comorbid major depression. A naturalistic study. Psychother Psychosom 69: 70-78
204. Ronalds C, Creed F, Stone K, Webb S, Tomenson B (1997) Outcome of anxiety and depressive disorders in primary care. Br J Psychiatry. 171: 427-433
205. Royal College of Psychiatrists (2000) Neurosurgery for mental disorder. Report from the Neurosurgery Working Group of the Royal College of Psychiatrists. Council Report CR89
206. Royal College of Psychiatrists (2005) Benzodiazepines: risks, benefits or dependence. A re-evaluation. Council Report CR 59
207. Roy-Byrne P P, Stang P, Wittchen H U, Ustun B, Walters E E, Kessler R C (2000) Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry 176: 229-235
208. Roy-Byrne P P, Stein M B, Russo J, Mercier E, Thomas R, McQuaid J, Katon W J, Craske M G, Bystritsky A, Sherbourne C D (1999) Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry 60: 492-499
209. Salvador-Carulla L, Segui J, Fernandez-Cano P, Canet J (1995). Costs and offset effects in panic disorders. Br J Psychiatry 166 (Suppl. 27): 23-28
210. Sartorius N, Ustun T B, Lecrubier Y, Wittchen H U (1996) Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry 30 (Suppl.): 38-43
211. Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T (1997) Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 58 (Suppl. 12): 7-10
212. Schatzberg A F, Haddad P, Kaplan E M, Lejoyeux M, Rosenbaum J F, Young A H, Zajecka J (1997) Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry 58 (Suppl. 7): 5-10
213. Schaub R T, Linden M (2000) Anxiety and anxiety disorders in the old and very old - results from the Berlin Aging Study (BASE). Compr Psychiatry 41 (Suppl. 1): 48-54
214. Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhausler H B, Kapfhammer H P (2001) The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry 50: 978-985
215. Schelling G, Kilger E, Roozendaal B, de Quervain D J, Briegel J, Dagge A, Rothenhausler H B, Krauseneck T, Nollert G, Kapfhammer H P (2004) Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry 55: 627-633
216. Shalev A Y, Freedman S, Peri T, Brandes D, Sahar T, Orr S P, Pitman R K (1998) Prospective study of posttraumatic stress disorder and depression following trauma. Am J Psychiatry 155: 630-637
217. Shannahoff-Kalsa D S, Ray L E, Levine S (1999) Randomised controlled trial of yogic meditation techniques for patients with obsessive-compulsive disorder. CNS Spectrums 4: 34-47
218. Sheehan D V, Raj A B, Sheehan K H, Soto S (1988) The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 29: 815-817
219. Shekelle P G, Woolf S H, Eccles M, Grimshaw J (1999) Clinical guidelines: developing guidelines. BMJ 318: 593-596
220. Silverstone P H, Salinas E (2001) Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 62: 523-539
221. Simpson H B, Liebowitz M R, Foa E B, Kozak M J, Schmidt A B, Rowan V, Petkova E, Kjernisted K, Huppert J D, Franklin M E, Davies S O, Campeas R (2004) Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety 19: 225-233
222. Souetre E, Lozet H, Cimarosti I (1994) Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 38: 151-160
223. Stahl S M, Gergel I, Li D (2003) Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64: 1322-1327
224. Stein D J, Ipser J C, Balkom A J (2004) Pharmacotherapy for social phobia. Cochrane Database Syst Rev Oct 18 (4): CD001206
225. Stein D J, Stein M B, Pitts C D, Kumar R, Hunter B (2002) Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 63: 152-155
226. Stein D J, Westenberg H G, Yang H, Li D, Barbato L M (2003) Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 6: 317-323
227. Stein D J, Zungu-Dirwayi N, Van der Linden GJH (2004) Pharmacotherapy for post traumatic stress disorder (PTSD). (Cochrane Review). In Cochrane Library, Issue 2. John Wiley & Sons, Ltd, Chichester, UK
228. Stein M B, Kline N A, Matloff J L (2002) Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 159: 1777-1779
229. Stein M B, Torgrud L J, Walker J R (2000) Social phobia symptoms, subtypes, and severity: findings from a community survey. Arch Gen Psychiatry 57: 1046-1052
230. Stein M B, Sareen J, Hami S, Chao J (2001) Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158: 1725-1727
231. Stein M B, Pollack M H, Bystritsky A, Kelsey J E, Mangano R M (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177: 280-288
232. Stein M B, Ron Norton G, Walker J R, Chartier M J, Graham R (2000) Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Psychiatry Res 94: 191-200
233. Stocchi F G, Nordera G, Jokinen R H (2003) Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64: 250-258
234. Taylor F B (2003) Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry 64: 1421-1425
235. Tiemens B G, Ormel J, Simon G E (1996) Occurrence, recognition, and outcome of psychological disorders in primary care. Am J Psychiatry 153: 636-644
236. Tiller J W, Bouwer C, Behnke K (1999) Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249 (Suppl. 1): S7-S10
237. Tollefson G D, Birkett M, Koran L, Genduso L (1994) Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 55 (Suppl.): 69-76
238. Tollefson G D, Rampey A H Jr, Potvin J H, Jenike M A, Rush A J, Kominguez R A, Koran L M, Shear M K, Goodman W, Genduso L A (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51: 559-67
239. Uhlenhuth E H, Balter M B, Ban T A, Yang K (1999) Benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety 9: 107-116
240. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research (1992) Acute pain management: operative or medical procedures and trauma. Agency for Health Care Policy and Research Publications, Rockville, MD
241. Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar C R (2003) Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 54: 947-949
242. Van Ameringen M, Mancini C, Wilson C (1996) Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 8: 115-121
243. Van Ameringen M, Allgulander C, Bandelow B, Greist J H, Hollander E, Montgomery S A, Nutt D J, Okasha A, Pollack M H, Stein D J, Swinson R P, World Council of Anxiety (2003). WCA recommendations for the long-term treatment of social phobia. CNS Spectrums 8 (Suppl. 1): 40-52
244. van Balkom A J, Bakker A, Spinhoven P, Blaauw B M, Smeenk S, Ruesink B (1997) A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 185: 510-516
245. van Boeijen C A, van Balkom A J, van Oppen P, Blankenstein N, Cherpanath A, van Dyck R (2005) Efficacy of self-help manuals for anxiety disorders in primary care: a systematic review. Fam Pract 22: 192-196
246. Van Etten M L, Taylor S (1998) Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clin Psychol Psychother 5: 126-145
247. van Vliet I M, Westenberg H G, Den Boer J A (1993) MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl) 772: 483-489
248. Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63: 31-37
249. Wagner K D, Berard R, Stein M B, Wetherhold E, Carpenter D J, Perera P, Gee M, Davy K, Machin A (2004) A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61: 1153-1162
250. Weiller E, Bisserbe J C, Maier W, Lecrubier Y (1998) Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health Care. Br J Psychiatry 34 (Suppl.): 18-23
251. Weiller E, Bisserbe J C, Boyer P, Lepine J P, Lecrubier Y (1996) Social phobia in general health care: an unrecognised undertreated disabling disorder. Br J Psychiatry 168: 169-174
252. Weissman A M, Levy B T, Hartz A J (2004) Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 161: 1066-1078
253. Weissman M M, Bland R C, Canino G J, Greenwald S, Hwu H G, Lee C K, Newman S C, Oakley-Browne M A, Rubio-Stipec M, Wickramaratne P J (1994) The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 55: 5-10
254. Wheadon D, Bushnell W, Steiner M (1993) A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. Poster presented at Annual Meeting of the American College of Neuro psychopharmacology, Honolulu, Hawaii, USA
255. Wittchen H U, Boyer P (1998) Screening for anxiety disorders. Sensitivity and specificity of the Anxiety Screening Questionnaire (ASQ-15). Br J Psychiatry 34 (Suppl.): 10-17
256. Wittchen H U, Jacobi F (2005) Size and burden of mental disorder in Europe: a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15: 357-376
257. Wittchen H U, Mühlig S, Beedso K (2003) Mental disorders in primary care. Dial Clin Neurosci 5: 115-128
258. Wittchen H U, Kessler R C, Pfister H, Lieb M (2000a) Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand 406 (Suppl.): 14-23
259. Wittchen H U, Carter R M, Pfister H, Montgomery S A, Kessler R C (2000b) Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 75: 319-328
260. Wittchen H U, Kessler R C, Beesdo K, Krause P, Hofler M, Hoyer J (2002) Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63 (Suppl. 8): 24-34
261. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, Geneva
262. World Health Organization (2004) WHO Guide to Mental and Neurological Health in Primary Care, 2nd edn. World Health Organization, Geneva. Accessible through www.mentalneurologicalprimarycare.org
263. Yonkers K A, Dyck I R, Warshaw M, Keller M B (2000) Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry 176: 544-549
264. Zigmond A S, Snaith R P (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361-370
265. Zohar A H, Ratzoni G, Pauls D L, Apter A, Bleich A, Kron S, Rappaport M, Weizman A, Cohen D J (1992) An epidemiological study of obsessive-compulsive disorder and related disorders in Israeli adolescents. J Am Acad Child Adolesc Psychiatry 31: 1057-1061